Multiple studies have found that the SF3B1 mutation uses an alternative cryptic 3’-splice site (3’Alternative Splice Site, A3SS) during splicing (26, 27), which may be a potential mechanism for its induction of splicing alterations in cancers such as MDS. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.